Pharmacological Depletion of Retinal Mononuclear Phagocytes is Neuroprotective in a Mouse Model of Mitochondrial Optic Neuropathy
Authors:
- Avital L. Okrent SmolarASAvital L. Okrent Smolar
- Rahul ViswanathRVRahul Viswanath
- Howard M. BomzeHBHoward M. Bomze
- Ying HaoYHYing Hao
- Sidney M. GospeSGSidney M. Gospe
Preprint
Abstract
Purpose: The Vglut2-Cre;ndufs4 loxP/loxP mouse strain with retinal ganglion cell (RGC)-specific mitochondrial complex I dysfunction develops severe RGC degeneration by postnatal day 90 (P90), with accompanying retinal mononuclear phagocyte (MNP) accumulation. We have reported that continuous exposure to hypoxia partially rescues RGC death in these mice, with minimal effect on MNP abundance. We hypothesized that pharmacological depletion of MNPs with the colony-stimulating factor-1 receptor inhibitor pexidartinib would enhance RGC neuroprotection by hypoxia. Methods: Iba1 + retinal MNP depletion was assessed in C57Bl/6J mice fed control or pexidartinib-infused chow beginning at P25. Subsequently, Vglut2-Cre;ndufs4 loxP/loxP mice and control littermates were raised under normoxia or hypoxia and fed control or pexidartinib chow from P25 to P90. The neuroprotective effect of pexidartinib and hypoxia alone and in combination was assessed by quantifying RGC soma and axon survival in retinal flat mounts and optic nerve cross sections. Results: Pexidartinib completely depleted retinal MNPs within one week of treatment. Untreated Vglut2-Cre;ndufs4 loxP/loxP mice exhibited the expected ∼50% reduction of RGC soma and axon survival at P90 (p<0.0001 for both). Hypoxia or pexidartinib monotherapy each reduced RGC degeneration by more than one-half, while their combination resulted in complete RGC neuroprotection (p<0.001 for all three treatments). Normal myelination patterns were restored in mice receiving dual therapy. Conclusions: Pexidartinib effectively depletes retinal MNPs and is neuroprotective in the setting of severe RGC mitochondrial dysfunction. This therapeutic effect is additive to that of hypoxia. Combating retinal neuro-inflammation may therefore be a useful adjunct therapy in mitochondrial optic neuropathies like Leber hereditary optic neuropathy.Keywords
Funding Information
- North American Neuro-Ophthalmology Society (Pilot Research Grant)
This publication has 42 references indexed in Scilit:
- The rAAV2-ND1 gene therapy for Leber hereditary optic neuropathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2025
- Microglial repopulation reverses cognitive and synaptic deficits in an Alzheimer’s disease model by restoring BDNF signalingBrain, Behavior, and Immunity, 2023
- Visual Outcomes and Optical Coherence Tomography Biomarkers of Vision Improvement in Patients With Leber Hereditary Optic Neuropathy Treated With IdebenoneAmerican Journal of Ophthalmology, 2022
- Microglial response promotes neurodegeneration in the Ndufs4 KO mouse model of Leigh syndromeGlia, 2022
- Leber hereditary optic neuropathy—new insights and old challengesGraefe's Archive for Clinical and Experimental Ophthalmology, 2020
- Pexidartinib: First ApprovalDrugs, 2019
- Bipolar cell reduction precedes retinal ganglion neuron loss in a complex 1 knockout mouse modelBrain Research, 2017
- Idebenone: A Review in Leber’s Hereditary Optic NeuropathyDrugs, 2016
- Leigh syndrome: One disorder, more than 75 monogenic causesAnnals of Neurology, 2015
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010